ResearcherSociedad Española de Oncología MédicaNo recent work listed
Ruth Vera
Matched on ORCID iD 0000-0003-0156-0029; OpenAlex author ID A5060205533. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 43
2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 5 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper
Papers 13
- Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14235993↗
- Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmed.2021.720128↗
- Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Last author DOI 10.1007/s12094-020-02350-6↗
- Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. Co-author DOI 10.3390/cancers12082181↗
- Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cance… Co-author DOI 10.1200/jco.18.00089↗
- Omics Approaches in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers11081052↗
- Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Co-author DOI 10.1007/s12094-016-1594-x↗
- Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies. Co-author DOI 10.1007/s12094-016-1609-7↗
- Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies. Co-author DOI 10.1007/s12094-017-1636-z↗
- Surgery for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-017-1688-0↗
- Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety … Co-author DOI 10.1016/j.ejca.2016.12.032↗
- SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Co-author DOI 10.1007/s12094-016-1586-x↗
- Stellate cells, a point of light in the dark night of pancreatic cancer. Last author DOI 10.1038/bjc.2014.59↗
Closest collaborators
The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joaquín Fernández‐Irigoyen · 4 shared papers, 2019–2022 · strength 0.40
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993↗
- Paper Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fmed.2021.720128↗
- Paper Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. DOI 10.3390/cancers12082181↗
- Antonio Viúdez · 4 shared papers, 2014–2022 · strength 0.35
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993↗
- Paper Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fmed.2021.720128↗
- Paper Omics Approaches in Pancreatic Adenocarcinoma. DOI 10.3390/cancers11081052↗
- Iranzu González‐Borja · 3 shared papers, 2019–2022 · strength 0.31
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993↗
- Paper Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fmed.2021.720128↗
- Paper Omics Approaches in Pancreatic Adenocarcinoma. DOI 10.3390/cancers11081052↗
- Roberto Pazo-Cid · 4 shared papers, 2017–2022 · strength 0.30
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993↗
- Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
- Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
- Emilia Alors‐Pérez · 2 shared papers, 2021–2022 · strength 0.23
- Justo Pastor Castano · 2 shared papers, 2021–2022 · strength 0.23
- Javier Gallego-Plazas · 3 shared papers, 2017–2022 · strength 0.22
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993↗
- Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
- Paper Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. DOI 10.1007/s12094-016-1594-x↗
- Elena Martín‐Pérez · 2 shared papers, 2017–2020 · strength 0.21
- Jaime Feliú · 2 shared papers, 2016–2022 · strength 0.18
- Teresa Mercade Macarulla · 3 shared papers, 2016–2019 · strength 0.18
- Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
- Paper SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). DOI 10.1007/s12094-016-1586-x↗
- Paper Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. DOI 10.1007/s12094-016-1594-x↗
- Joaquina Martínez-Galán · 3 shared papers, 2017–2019 · strength 0.17
- Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
- Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
- Paper Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. DOI 10.1007/s12094-016-1594-x↗
- Carmen Guillén‐Ponce · 3 shared papers, 2017–2019 · strength 0.17
- Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
- Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
- Paper Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. DOI 10.1007/s12094-016-1594-x↗
- Fernando Rivera Herrero · 2 shared papers, 2017–2019 · strength 0.13
- Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
- Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
- Carlos Plaza Hernandezv · 2 shared papers, 2017 · strength 0.13
- Alfredo Carrato Mena · 2 shared papers, 2017 · strength 0.13
- J. Enrique Domínguez‐Muñoz · 1 shared paper, 2020 · strength 0.13
- Ismael Ghanem · 1 shared paper, 2022 · strength 0.13
- Manuel M. Hidalgo · 2 shared papers, 2017–2019 · strength 0.12
- Jorge Aparicio · 2 shared papers, 2017 · strength 0.12
- Paper Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between … DOI 10.1007/s12094-016-1609-7↗
- Paper Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consen… DOI 10.1007/s12094-017-1636-z↗
- Eva Cristina Vaquero · 2 shared papers, 2017 · strength 0.12
- Paper Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between … DOI 10.1007/s12094-016-1609-7↗
- Paper Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consen… DOI 10.1007/s12094-017-1636-z↗
- José Luis Manzano Mozo · 2 shared papers, 2016–2017 · strength 0.11
- Mercedes Salgado · 2 shared papers, 2016–2017 · strength 0.10
- Hugo Arasanz Esteban · 1 shared paper, 2020 · strength 0.09
- Grazyna T. Kochan · 1 shared paper, 2020 · strength 0.09
- Pablo Sala Elarre · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.